Recombinant Human Semaphorin 3B Fc Chimera Protein, CF

When Recombinant Human Semaphorin 3B Fc Chimera (Catalog # 9618-S3) is coated at 1 μg/mL, 100 μL/well, it binds to Recombinant Rat Neuropilin‑1 Fc Chimera (Catalog # 566‑N1) with an ED50 of 25‑150 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Semaphorin 3B Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Semaphorin 3B Fc Chimera is coated at 1 μg/mL, 100 μL/well, it binds to Recombinant Rat Neuropilin‑1 Fc Chimera (Catalog # 566-N1) with an ED₅₀ of 25-150 ng/mL.
• Source: Trichoplusia ni, T. ni (baculovirus)-derived human Semaphorin 3B protein
  

  Human Semaphorin 3B (Ala25-Gly727(Arg551Ala, Arg554Ala)) Accession # Q13214-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q13214-1
• N-terminal Sequence: Ala25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 105 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 96-116 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Citric Acid, NaCl and Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Semaphorin 3B Fc Chimera Protein, CF

• (semaphorin) 3B
• LUCA-1
• Sema A(V)
• sema domain, immunoglobulin domain (Ig), short basic domain, secreted
• Sema V
• SemA
• SEMA3B
• SEMA5
• SEMA5FLJ34863
• SEMAA
• Semaphorin 3B
• semaphorin A
• semaphorin V
• semaphorin-3B
• semaphorin-V
• SEMAV

Background

Semaphorin 3B (Sema3B), also known as Semaphorin V and Sema A(V), is an approximately 90 kDa member of the semaphorin family that plays a role in cancer, neuronal and vascular development (1-4). Class 3 semaphorins are secreted molecules found in vertebrates and contain a common domain structure. The Sema3B domains consist of a 484 aa Sema domain, followed by a plexin-semaphorin-integrin (PSI) domain, an 87 aa Ig-like C2-type domain, and a 21 aa basic domain (5). Within these domains, human Sema3B shares 88% and 90% aa sequence identity with mouse and rat Sema3B, respectively. Like other Class 3 semaphorins, Sema3B signaling is transduced by a transmembrane plexin-A dimer, which also has a Sema domain and is coupled to kinase pathways (6, 7). Sema3B binds indirectly to plexins, and requires interaction with neuropilins for activity (6, 7). Repulsive signals through Neuropilin-1 (Npn-1) and attractive signals through Neuropilin-2 (Npn-2) have been identified, affecting adhesion molecule activity in opposite directions (6, 8). In tumors, Sema3B competes with VEGF165 for binding to Npn-1, which in part down-regulates tumor angiogenesis, inhibits tumor cell proliferation and promotes apoptosis (9, 10). However, it is also proposed to promote dissemination and metastatic progression by stimulating Npn-1 mediated IL-8 secretion in a subset of tumors that over-express Sema3B (11). In differentiating osteoblasts, Sema3B expression is induced by vitamin D and promotes osteoclastogenesis (12).

1. Sekido, Y. et al. (1996) Proc Natl Acad Sci U S A. 93:4120.
2. Gu, C. and E. Giraudo. (2013) Exp. Cell Res. 319:1306.
3. Sabag, A. et al. (2012) PLoS One. 7:e42912.
4. Aghajanian, H. et al. (2014) J. Biol. Chem. 289:17971.
5. Yazdani, U. and J. Terman. (2006) Genome Biology. 7:211.
6. Halloran, M. C. and M. A. Wolman (2006) Curr. Opin. Cell Biol. 18:533.
7. Neufeld, G. and O. Kessler (2008) Nat. Rev. Cancer 8:632.
8. Falk, J. et al. (2005) Neuron 48:63.
9. Castro-Rivera, E. et al. (2004) Proc. Natl. Acad. Sci. USA 101:11432.
10. Koyama, N. et al. (2008) Oncogene 27:6581.
11. Rolny, C. et al. (2008) J. Exp. Med. 205:1155.
12. Sutton, A. L. M. et al. (2008) Mol. Endocrinol. 22:1370.

Publications for Semaphorin 3B (9518-S3)(1)

Publication using 9518-S3

• MW Tang, B Malvar Fer, SP Newsom, JD van Buul, TRDJ Radstake, DL Baeten, PP Tak, KA Reedquist, S García Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes Rheumatology (Oxford), 2018-05-01;0(0):. 2018-05-01 [PMID: 29471421] (Stimulation, Human)

Bioinformatics

• Uniprot:
  • Q13214-1()